Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered t cells take aim at Hard-to-Treat breast cancer

NCT ID NCT02792114

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests the safety of specially prepared T cells that target a protein called mesothelin, found on some breast cancer cells. The cells are collected from the patient's blood, modified in a lab, and then given back along with chemotherapy and another drug. The trial enrolls adults with metastatic HER2-negative breast cancer who have already tried at least one chemotherapy. The goal is to find a safe dose of these modified T cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a specially prepared T cell therapy that targets mesothelin, given with cyclophosphamide and AP1903
What this could lead to
If successful, this could point toward a new treatment option for metastatic HER2-negative breast cancer that is resistant to standard therapies.
What could go wrong
This is an early phase I trial focused on safety, so it is too soon to know if the treatment will be effective. There may be significant side effects from the modified T cells or the chemotherapy used to prepare the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC HER2-NEGATIVE BREAST

Contacts and locations

Locations

  • Memorial Sloan Kettering Bergen (Consent and follow-up only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center (Consent and follow-up only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center at Commack (Consent and follow-up only)

    Commack, New York, United States

  • Memorial Sloan Kettering Monmouth (Consent and follow-up only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent and Follow-Up only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Consent and follow-up only)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.